Benzinga··Vandana SinghBridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside
BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development